The efficacy and safety of setmelanotide in individuals with Bardet-Biedl syndrome or Alström syndrome: Phase 3 trial design.

Haws, Robert M; Gordon, Gregory; Han, Joan C; Yanovski, Jack A; Yuan, Guojun; Stewart, Murray W

Haws, Robert M; Gordon, Gregory; Han, Joan C; Yanovski, Jack A; Yuan, Guojun; Stewart, Murray W.

Afiliação

Haws RM; Marshfield Clinic Research Institute, Marshfield, WI, USA.
Gordon G; Rhythm Pharmaceuticals, Inc, Boston, MA, USA.
Han JC; University of Tennessee Health Science Center, Memphis, TN, USA.
Yanovski JA; Children's Foundation Research Institute, Le Bonheur Children's Hospital, Memphis, TN, USA.
Yuan G; Section on Growth and Obesity, Eunice Kennedy Schriver National Institute of Child Health and Human Development, National Institute of Health, Bethseda, MD, USA.
Stewart MW; Rhythm Pharmaceuticals, Inc, Boston, MA, USA.

Contemp Clin Trials Commun ; 22: 100780, 2021 Jun.

Article em En | MEDLINE | ID: mdl-34013094

Palavras-chave

Antiobesity drug; Appetite control; Obesity therapy; Phase III study

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline Idioma: En Revista: Contemp Clin Trials Commun Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google